Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2026)

Xilio Therapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $35.3 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 50.19% year-over-year to $35.3 million; the TTM figure through Jun 2026 stood at $35.3 million (down 50.19% YoY), while the FY2025 annual figure was $60.7 million, up 85.05% from the prior year.
• Current Deferred Revenue came in at $35.3 million for Q2 2026 at Xilio Therapeutics, down from $48.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $79.0 million in Q1 2025 to a low of $21.7 million in Q1 2024.
• Average Current Deferred Revenue over 3 years is $47.0 million, with a median of $41.7 million recorded in 2026.
• Year-over-year, Current Deferred Revenue jumped 263.61% in 2025 and plunged 50.19% in 2026.
• Over 3 years, Current Deferred Revenue stood at $32.8 million in 2024, then jumped by 85.05% to $60.7 million in 2025, then tumbled by 41.78% to $35.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $35.3 million in Q2 2026, $48.0 million in Q1 2026, and $60.7 million in Q4 2025.